QualityStocks would like to highlight NanoViricides Inc. (OTCBB: NNVC). NanoViricides is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.
In the company’s news yesterday,
NanoViricides Inc. announced it has selected a clinical candidate, now designated NV-INF-1, for FDA submission in its highly successful FluCide™ anti-influenza therapeutics program. Based on NV-INF-1′s demonstrated efficacy as a highly effective anti-influenza drug in animal studies, NanoViricides said it believes the candidate will be rapidly and widely recognized as treatment for severe influenza.
FDA consultants are assisting the company in developing additional information on NV-INF-1 to prepare for the pre-IND application to the FDA.
NV-INF-1 is expected to be effective against most strains and types of influenzas, including novel epidemic influenza strains such as the swine flu; seasonal flu such as H1N1, H3N2; highly pathogenic types such as H7N and H9N; and the “bird flu,” or H5N1. The company plans on designating NV-INF-1 for two separate indications: high strength dosage form for hospitalized patients with severe influenza; and a single course therapy for the out-patients with less severe influenza.
The company noted that the market size for anti-influenza drugs is currently estimated to be approximately $4 billion-$7 billion worldwide. If its FluCide™ drug becomes available, the company anticipates that the market could significantly increase.
Previous studies showed high efficacy for its optimized FluCide™ drug candidates, prompting the company to focus its efforts on advancing one of the tested optimized FluCide candidates as the clinical drug candidate.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net
Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
